Scott M. Rocklage, PhD joined 5AM Ventures in 2003, and he has since become a managing partner for the company. Prior to this experience, Rocklage has worked within the medical industry for over thirty years; contributing to the FDA approval of three important U.S. New Drug Applications, along with entering a variety of drugs to receive further clinical trials, Scott Rocklage remains successful with his proven, managerial experience.
Before working for 5AM Ventures, Scott served as Chairman and CEO of Cubist Pharmaceuticals and President and CEO of Nycomed Salutar, to name a few of his essential positions in prominent companies.
Along with his experience directly managing medical companies, he serves on the board of directors for a number of drug and chemical agencies. When attending university studies, Rocklage received his B.S. in Chemistry from the University of California, Berkeley, and he achieved his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), one of the most influential and important schools in the nation, where he worked alongside Nobel Prize winner in Chemistry, Richard R. Schrock.
Scott remains active in directing operations for a plethora of companies that impact public health in the United States and abroad. Even with his decades of experience managing companies, Scott Rocklage also enjoys inventing in his free time; he has dozens of patents for his ideas, while also contributing to the peer reviews of over a hundred scientific publications.
Scott M. Rocklage is an expert in his craft and will go down in history as a vital leader, with a proven track record for managing successful medical companies.